Financial Performance - The company's revenue for Q1 2023 reached ¥845,614,829.78, representing a 24.91% increase compared to ¥676,978,835.10 in the same period last year[5] - Net profit attributable to shareholders was ¥29,483,336.47, a significant increase of 90.94% from ¥15,441,235.95 in the previous year[5] - Basic and diluted earnings per share increased by 80.40%, reaching ¥0.0819 per share, up from ¥0.0454 per share in the prior year[5] - Total operating revenue for Q1 2023 reached ¥845,614,829.78, an increase of 25% compared to ¥676,978,835.10 in Q1 2022[28] - Net profit for Q1 2023 was ¥29,158,078.38, representing a 89.5% increase from ¥15,393,421.16 in Q1 2022[29] - Basic and diluted earnings per share for Q1 2023 were both ¥0.0819, compared to ¥0.0454 in Q1 2022, marking an increase of 80.5%[30] Cash Flow and Liquidity - The net cash flow from operating activities surged by 198.46%, amounting to ¥205,224,849.16 compared to ¥68,760,834.52 in Q1 2022[5] - Cash inflow from operating activities totaled CNY 966,968,925.08, compared to CNY 531,308,574.21 in the previous period, indicating a rise of about 82.0%[33] - Cash outflow from operating activities increased to CNY 761,744,075.92 from CNY 462,547,739.69, reflecting a growth of approximately 64.6%[33] - The net cash flow from investing activities was CNY -134,666,915.68, worsening from CNY -27,291,232.81 in the previous period[33] - Total cash and cash equivalents at the end of the period amounted to CNY 974,774,620.88, compared to CNY 62,179,722.89 at the end of the previous period, indicating a substantial increase of approximately 1465.5%[33] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,614,598,263.03, reflecting a 40.31% increase from ¥2,576,184,947.30 at the end of the previous year[5] - Total liabilities increased to ¥1,755,989,375.54 in Q1 2023 from ¥1,629,179,024.60 in Q1 2022, a rise of 7.8%[26] - The company's equity attributable to shareholders reached ¥1,858,348,878.58, significantly up from ¥947,278,655.70 in the previous year, reflecting a growth of 96.3%[26] Research and Development - The company's R&D expenses rose dramatically by 705.83%, totaling ¥2,027,569.40, compared to ¥251,612.14 in the same quarter last year, indicating increased investment in innovation[9] - Research and development expenses for Q1 2023 were ¥2,027,569.40, compared to ¥251,612.14 in Q1 2022, showing a substantial increase of 705.5%[28] Shareholder Information - The major shareholder, He Jiale, holds 50.12% of the shares, totaling 200,493,326 shares[12] - Alibaba Health Technology (China) Co., Ltd. is the second-largest shareholder with 7.51%, holding 30,049,373 shares[12] - The company has a total of 10 major shareholders, with the top 10 holding significant stakes in the company[12] - The total number of restricted shares held by He Jiale is 200,493,326, which will be released on March 1, 2026[14] - The company reported that the first quarter of 2023 has seen no changes in the number of restricted shares for major shareholders[14] - The company is focused on maintaining its market position and expanding its shareholder base through strategic partnerships[12] - The first quarter report indicates a stable shareholding structure with no new major investors entering the market[14] Acquisitions and Expansion - The company acquired 100% equity of Huangshan Xin'anjiang Pharmacy Chain Co., Ltd. for RMB 32.98 million, involving 27 stores[19] - The company completed the acquisition of 70% equity of Anhui Shouzhou Huaren Pharmacy Chain Co., Ltd. for RMB 10.69 million, involving 23 stores[21] - The company has plans for market expansion in Anhui, Jiangsu, and Henan provinces, focusing on enhancing brand influence and regional leadership[16] - The company has a total of 58 self-built stores and 51 acquired stores in the Anhui province as part of its strategic expansion[17] - The company is actively developing its franchise business to strengthen its marketing network and brand presence[16] Financing Activities - The company raised a total of RMB 974.56 million from the issuance of 60.01 million A shares at a price of RMB 16.24 per share, with a net amount of RMB 879.45 million after deducting issuance costs[18] - The company is actively involved in financing and margin trading, with several major shareholders participating in these activities[13] - The company received CNY 907,734,283.02 from investment absorption, a notable increase as it was CNY 0.00 in the previous period[33] - The company paid CNY 117,479,505.06 for debt repayment, which is an increase from CNY 43,000,000.00 in the previous period, reflecting a growth of approximately 173.3%[33]
华人健康(301408) - 2023 Q1 - 季度财报